These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 10215758)

  • 1. Is reporting rate a good predictor of risks associated with drugs?
    Pierfitte C; Bégaud B; Lagnaoui R; Moore ND
    Br J Clin Pharmacol; 1999 Mar; 47(3):329-31. PubMed ID: 10215758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy.
    Motola D; Vargiu A; Leone R; Conforti A; Moretti U; Vaccheri A; Velo G; Montanaro N
    Drug Saf; 2008; 31(7):609-16. PubMed ID: 18558794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports?
    Svendsen K; Halvorsen KH; Vorren S; Samdal H; Garcia B
    Eur J Clin Pharmacol; 2018 Apr; 74(4):497-504. PubMed ID: 29255992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
    Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
    Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updating the French method for the causality assessment of adverse drug reactions.
    Arimone Y; Bidault I; Dutertre JP; Gérardin M; Guy C; Haramburu F; Hillaire-Buys D; Meglio C; Penfornis C; Théophile H; Valnet-Rabier MB;
    Therapie; 2013; 68(2):69-76. PubMed ID: 23773347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statistical and graphical approaches for disproportionality analysis of spontaneously-reported adverse events in pharmacovigilance.
    Zink RC; Huang Q; Zhang LY; Bao WJ
    Chin J Nat Med; 2013 May; 11(3):314-20. PubMed ID: 23725848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using Data from the Canadian Post-marketing Spontaneous Pharmacovigilance System for Drug Safety Research: A Feasibility Study.
    Akinola S; da Silveira CG; Corbin S; Lavallée M; Thibault M; Gonella J; Gimenes FRE; Leclerc J
    Pharmaceut Med; 2020 Aug; 34(4):263-269. PubMed ID: 32671791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-daily Extended-release Methylphenidate Medications in Canada: Analysis of Spontaneous Adverse Event Reporting Databases.
    Park-Wyllie L; van Stralen J; Castillon G; Sherman SE; Almagor D
    Clin Ther; 2017 Oct; 39(10):2006-2023. PubMed ID: 28988700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001).
    Thiessard F; Roux E; Miremont-Salamé G; Fourrier-Réglat A; Haramburu F; Tubert-Bitter P; Bégaud B
    Drug Saf; 2005; 28(8):731-40. PubMed ID: 16048358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias.
    Pariente A; Gregoire F; Fourrier-Reglat A; Haramburu F; Moore N
    Drug Saf; 2007; 30(10):891-8. PubMed ID: 17867726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of stratification on adverse drug reaction surveillance.
    Hopstadius J; Norén GN; Bate A; Edwards IR
    Drug Saf; 2008; 31(11):1035-48. PubMed ID: 18840023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug makers' adverse event reports are often incomplete, US report finds.
    McCarthy M
    BMJ; 2015 Feb; 350():h651. PubMed ID: 25652561
    [No Abstract]   [Full Text] [Related]  

  • 13. Interstitial Lung Disease as an Adverse Drug Reaction in Japan: Exploration of Regulatory Actions as a Basis for High Reporting.
    Iwasa E; Fujiyoshi Y; Kubota Y; Kimura R; Chandler RE; Taavola H; Norén GN; Wakao R
    Drug Saf; 2020 Nov; 43(11):1121-1131. PubMed ID: 32617874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluvastatin and hepatic reactions: a signal from spontaneous reporting in Italy.
    Conforti A; Magro L; Moretti U; Scotto S; Motola D; Salvo F; Ros B; Leone R
    Drug Saf; 2006; 29(12):1163-72. PubMed ID: 17147462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal trends in spontaneous reporting of unlabelled adverse drug reactions.
    Haramburu F; Bégaud B; Moride Y
    Br J Clin Pharmacol; 1997 Sep; 44(3):299-301. PubMed ID: 9296328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signal selection and follow-up in pharmacovigilance.
    Meyboom RH; Lindquist M; Egberts AC; Edwards IR
    Drug Saf; 2002; 25(6):459-65. PubMed ID: 12071784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing the spontaneous reporting of adverse drug reactions--the experience of the Slovak Republic.
    Tisonová J; Szalayová A; Kriska M; Gibala P; Foltán V
    Pharmacoepidemiol Drug Saf; 2004 May; 13(5):333-7. PubMed ID: 15133786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Weber-curve pitfall: effects of a forced introduction on reporting rates and reported adverse reaction profiles.
    de Graaf L; Fabius MA; Diemont WL; van Puijenbroek EP
    Pharm World Sci; 2003 Dec; 25(6):260-3. PubMed ID: 14689813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
    Alatawi YM; Hansen RA
    Expert Opin Drug Saf; 2017 Jul; 16(7):761-767. PubMed ID: 28447485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.